Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. While the media's attention has focused on unproven links between ...

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in ...

Vaccine development is traditionally driven by financial return opportunities for investors, disease outbreaks, and a specific focus on emerging diseases. However, a new systematic, transparent, and ...

Vaccine development for aquaculture species encompasses a diverse array of approaches designed to prevent bacterial, viral and parasitic diseases in farmed fish. Conventional strategies include ...

Vaccinations have revolutionized healthcare, but designing them remains complex, requiring time and creativity, especially for vaccines against viruses, which are difficult to study. “Each virus ...

Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising ...

Doctors battling a rare strain of Ebola in central Africa will probably need to wait many months for a vaccine to be ready ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

Shionogi & Co. looks set to put its COVID-19 vaccine into practical use by the end of March 2022 following a government ...

A hantavirus vaccine is currently in preclinical development, but a publicly available shot is likely years away. Other similar research efforts are also in the very early stages.

Vaccines are the most efficacious means of minimizing the impact of infectious diseases on the human population. The challenges and importance of making vaccines that will meet FDA approval have never ...